CS
MACK

Credit Suisse’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Credit Suisse’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-55,566
Closed -$635K – 4384
2017
Q3 		$635K Buy
55,566
+41,407
+292% +$435K ﹤0.01% 3405
2017
Q2 		$138K Sell
14,159
-33,445
-70% -$683K ﹤0.01% 3689
2017
Q1 		$1.15M Buy
47,604
+21,762
+84% +$544K ﹤0.01% 2762
2016
Q4 		$829K Sell
25,842
-19,542
-43% -$833K ﹤0.01% 3149
2016
Q3 		$2.27M Sell
45,384
-3,153
-6% -$131K ﹤0.01% 2284
2016
Q2 		$2.06M Buy
48,537
+2,542
+6% +$138K ﹤0.01% 2315
2016
Q1 		$3.03M Buy
45,995
+5,459
+13% +$285K ﹤0.01% 1890
2015
Q4 		$2.52M Buy
40,536
+3,013
+8% +$212K ﹤0.01% 2117
2015
Q3 		$2.51M Sell
37,523
-18,616
-33% -$1.52M ﹤0.01% 2085
2015
Q2 		$5.46M Buy
56,139
+12,291
+28% +$1.17M 0.01% 1665
2015
Q1 		$4.1M Sell
43,848
-27,542
-39% -$2.34M ﹤0.01% 1822
2014
Q4 		$6.35M Buy
71,390
+1,819
+3% +$133K 0.01% 1586
2014
Q3 		$4.81M Buy
69,571
+6,483
+10% +$346K ﹤0.01% 1777
2014
Q2 		$3.62M Buy
63,088
+37,002
+142% +$1.88M ﹤0.01% 2234
2014
Q1 		$1.03M Sell
26,086
-78,111
-75% -$3.34M ﹤0.01% 3089
2013
Q4 		$4.37M Sell
104,197
-291,548
-74% -$8.45M ﹤0.01% 1965
2013
Q3 		$11.8M Sell
395,745
-189,831
-32% -$6.64M 0.01% 1028
2013
Q2 		$31.1M Buy
+585,576
New +$25.7M 0.03% 551

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Credit Suisse's MACK Position: Q4 2017 in Review

Credit Suisse sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 55,566 shares — an estimated $635K sold.

Credit Suisse first reported a position in MACK in Q2 2013 and held it in 18 quarters. The position peaked at $31.1M in Q2 2013. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

  • Credit Suisse reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Credit Suisse sold 55,566 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $635K.
  • Credit Suisse first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 18 quarters.
  • Credit Suisse's Merrimack Pharmaceuticals, Inc. position peaked at $31.1M in Q2 2013.
  • 78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on Credit Suisse's 13F filing for Q4 2017, filed 14 Feb 2018.